The goal of the 2015 Michigan Appropriateness Guide for Intravenous Catheters (MAGIC) was to define indications and appropriate practices for peripherally inserted central catheters (PICC) use; however, MAGIC recommendations virtually reduced the use of PICC in hospital settings, including critical care. The aim of this review is to present an assessment of the MAGIC guidelines, considering contemporary evidence to date. The validity of the MAGIC recommendations and their applicability to current practice are called into question given important concerns with the methodology for their development (e.g. high volume of clinical scenarios for evaluation) and the supporting evidence used. There is a considerable amount of contemporary evidence not considered in MAGIC that reports on evolving practices, techniques, and technologies targeted to reduce complications associated with central venous access devices (CVADs). Recent evidence dictates that CVADs are necessary in the intensive care unit (ICU), and that PICCs are a safe, reliable, and appropriate type of central lines, which cannot be replaced in several ICU situations. In light of evolving evidence and practice, as well as the methodological concerns identified, the MAGIC guidelines should be revisited. It is also recommended to create a clinical assessment tool that identifies potential uses of specific CVADs, based on patient needs. The choice of the CVAD should be based on unique clinical considerations and current scientific evidence, not on fears informed by antiquated data.

Download full-text PDF

Source
http://dx.doi.org/10.1177/11297298211048019DOI Listing

Publication Analysis

Top Keywords

magic recommendations
12
assessment magic
8
evolving evidence
8
magic guidelines
8
contemporary evidence
8
evidence
7
magic
6
recommendations context
4
context evolving
4
evidence based
4

Similar Publications

Objective: To examine the evidence addressing the management of X-linked hypophosphatemia (XLH) in children to inform treatment recommendations.

Methods: We searched Embase, MEDLINE, Web of Science, and Cochrane Central up to May 2023. Eligible studies included RCTs and observational studies of individuals less than 18yrs with clinically or genetically confirmed XLH.

View Article and Find Full Text PDF

Before October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a pneumococcal conjugate vaccine (PCV) for all adults aged ≥65 years, as well as for those aged 19-64 years with risk conditions for pneumococcal disease who have not received a PCV or whose vaccination history is unknown. Options included either 20-valent PCV (PCV20; Prevnar20; Wyeth Pharmaceuticals) or 21-valent PCV (PCV21; CAPVAXIVE; Merck Sharp & Dohme) alone or 15-valent PCV (PCV15; VAXNEUVANCE; Merck Sharp & Dohme) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax23; Merck Sharp & Dohme). There are additional recommendations for use of PCV20 or PCV21 for adults who started their pneumococcal vaccination series with 13-valent PCV (PCV13; Prevnar13; Wyeth Pharmaceuticals).

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the most reliable evidence for managing X-linked hypophosphatemia (XLH) in adults to help shape treatment recommendations.
  • After reviewing over 4,000 records, only one clinical trial and two observational studies met the criteria, showing that burosumab likely helps with pain from fractures but has a limited effect on other symptoms like fatigue and stiffness.
  • There are currently no strong comparisons between burosumab and conventional treatments, highlighting a significant gap in data regarding their long-term effectiveness on important patient outcomes.
View Article and Find Full Text PDF

Introduction: This systematic review and meta-analysis provides estimates of major complications and blood loss for open partial nephrectomy, conventional laparoscopic partial nephrectomy, and robot-assisted partial nephrectomy. Additionally, it outlines the incidence of major complications associated with percutaneous thermal ablation in patients with small renal masses.

Methods: We searched MEDLINE, EMBASE, and CINAHL from inception to the end of July 2023.

View Article and Find Full Text PDF

Identifying and Quantifying Borate Environments in Borosilicate Glasses: B NMR-Peak Assignments Assisted by Double-Quantum Experiments.

J Phys Chem B

December 2024

Physical Chemistry Division, Department of Materials and Environmental Chemistry, Arrhenius Laboratory, Stockholm University, Stockholm SE-106 91, Sweden.

We discuss the prospects for accurate B magic-angle-spinning (MAS) nuclear magnetic resonance (NMR) spectral deconvolutions for reaching beyond the readily extracted borate speciations offered by the integrated resonances of the coexisting B and B species of the respective BO and BO network groups in borosilicate (BS) glasses. We critically review hitherto proposed B and B NMR-peak assignments relating to their neighboring Si, B and B species, as quantified by MAS NMR spectral deconvolution. Guidance to these resonance assignments was offered from double-quantum-single-quantum (2Q-1Q) B MAS NMR experiments that inform about the B-O-B network linkages.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!